Evidence map›Paper›PMID 25308292›Full record

ReviewLeukemia & lymphoma2015

Paradigm shifts in the management of poor-risk chronic lymphocytic leukemia.

Racquel D Innis-Shelton, Randall S Davis, Lawrence Lamb, Shin Mineishi

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Leukemia & lymphoma, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Racquel D Innis-SheltonDivision of Hematology and Oncology, BMT and CT Program, Department of Internal Medicine, UAB Hosptial, University of Alabama at Birmingham Comprehensive Cancer Center , Birmingham, AL , USA.
Randall S Davis
Lawrence Lamb
Shin Mineishi

Funding

Validating a novel biomarker of clinical progression and survival in CLLR33CA161731 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DAVIS, RANDALL S · 2011 to 2013
$1.1M
Cellular and Biologic Origins of CLLR21CA175912 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DAVIS, RANDALL S · 2014 to 2015
$352k
NCI NIH HHS CA161731NCI NIH HHS CA175912NCI NIH HHS R21 CA175912NCI NIH HHS R33 CA161731
6 · The paper itself

Abstract

With the growing complexity of treatment options for chronic lymphocytic leukemia (CLL) and variables that influence the underlying biology of this disease, providing allogeneic stem cell transplant (alloSCT) to appropriate candidates poses a challenge for transplant physicians. Novel small molecule inhibitors hold unprecedented promise for poor-risk subgroups, which will likely alter decision-making and referral patterns for transplant. In this review, we analyze what is known and may still remain true about indications for transplant based on outcomes reported in the literature recently and over the last decade.

Indexed as

Stem Cell TransplantationHumansLeukemia, Lymphocytic, Chronic, B-CellPrognosisTransplantation, HomologousAllogeneicchronic lymphocytic leukemiastem cell transplant

Identifiers

PMID25308292
PMCPMC13058952

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.